Skip to search formSkip to main contentSkip to account menu

MORAb-003

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

farletuzumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
A randomized, double-blind, placebo-controlled, phase II study to assess the efficacy and safety of farletuzumab (MORAb-003) in combination with carboplatin plus either paclitaxel or pegylated…
TPS5608Background: Farletuzumab (FAR) is a humanized monoclonal antibody that binds to folate receptor-alpha which is highly… 
2015
2015
Abstract 3817: Suicidal autophagy induced by immunotherapy targeting folate receptor in ovarian cancer
Objective Cancer cells depend on folate metabolism for DNA replication, making folate receptor alpha (FRα) an important… 
2010
2010
A randomized, double-blind, placebo-controlled phase II study of the efficacy and safety of farletuzumab (MORAb-003) in combination with weekly paclitaxel in subjects with platinum-resistant or…
TPS255 Background: Farletuzumab (MORAb-003) is a humanized monoclonal antibody that binds to the folate receptor alpha (FRA… 
2010
2010
Modulators of Response to Tumor Necrosis-Factor-related Apoptosis Inducing Ligand (TRAIL) Therapy in Ovarian Cancer PRINCIPAL INVESTIGATOR:
2008
2008
Exploratory phase II efficacy study of MORAb-003, a monoclonal antibody against folate receptor alpha, in platinum-sensitive ovarian cancer in first relapse
5500 Background: Folate receptor alpha (FRA) is over-expressed in the majority of epithelial ovarian cancers (EOC) but largely… 
2007
2007
MORAb-003, a fully humanized monoclonal antibody against the folate receptor alpha, for the potential treatment of epithelial ovarian cancer.
Morphotek Inc is developing MORAb-003, a humanized monoclonal antibody directed against folate receptor alpha, for the potential… 
2007
2007
A phase I study of MORAb-003, a fully humanized monoclonal antibody against folate receptor alpha, in advanced epithelial ovarian cancer
5517 Background: MORAb-003 (M3) is a humanized monoclonal antibody against the folate receptor alpha (FRA) which is over… 
2007
2007
Novel phase II study design of MORAb-003, a monoclonal antibody against folate receptor alpha in platinum-sensitive ovarian cancer in first relapse
5583 Background: Folate receptor alpha (FRA) is over-expressed in the majority of epithelial ovarian cancers (EOC) but largely… 
2006
2006
Phase I study of MORAb-003, a humanized anti-folate receptor-alpha monoclonal antibody, in platinum resistant ovarian cancer.
5027 Background: Folate receptor alpha (FRA) is over-expressed in the majority of epithelial ovarian cancers (EOC) but largely… 
2006
2006
MORAb-003 inhibits folate-driven growth mediated by the human folate receptor alpha.
10108 Background: MORAb-003 is a therapeutic humanized antibody currently in Phase I clinical trials for advanced ovarian cancer… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)